CHRU Brest, Hôpital de la Cavale Blanche, Département de Neurologie, Faculté de Médecine et des Sciences de la Santé, INSERM U-613 de Brest, Brest, France.
Clin Pharmacol Ther. 2012 Feb;91(2):327-32. doi: 10.1038/clpt.2011.312. Epub 2012 Jan 4.
Stroke is the third most common cause of mortality and the leading cause of disability in industrialized country. According to population based-studies, ischemic stroke accounts for 67-80% of all strokes. Thrombolysis is used during the acute phase in only 2-5% of ischemic patients. Clinical trials of candidate neuroprotective agents have failed to identify viable therapies for ischemic stroke in humans. There is therefore a great need for new therapeutic strategies, considering that not all brain cells die immediately after ischemic stroke.
中风是全球范围内致死率排名第三的疾病，也是导致残疾的首要原因。基于人群的研究表明，缺血性中风占所有中风的 67-80%。只有 2-5%的缺血性中风患者在急性期接受溶栓治疗。候选神经保护剂的临床试验未能在人类缺血性中风中确定可行的治疗方法。因此，鉴于并非所有脑细胞在缺血性中风后都会立即死亡，非常需要新的治疗策略。
